Jounce Therapeutics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
April 29, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
July 23, 2019 16:00 ET
|
Jounce Therapeutics, Inc.
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
March 06, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with...